Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes

The Cochrane Database of Systematic Reviews
Franz HutzschenreuterNicole Skoetz

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of haematological diseases which are characterised by a uni- or multilineage dysplasia of haematological stem cells. Standard treatment is supportive care of the arising symptoms including red blood cell transfusions or the administration of erythropoiesis-stimulating agents (ESAs) in the case of anaemia or the treatment with granulocyte (G-CSF) and granulocyte-macrophage colony stimulating factors (GM-CSF) in cases of neutropenia. The objective of this review is to assess the evidence for the treatment of patients with MDS with G-CSF and GM-CSF in addition to standard therapy in comparison to the same standard therapy or the same standard therapy and placebo. We searched MEDLINE (from 1950 to 3 December 2015) and CENTRAL (Cochrane Central Register of Controlled Trials until 3 December 2015), as well as conference proceedings (American Society of Hematology, American Society of Clinical Oncology, European Hematology Association, European Society of Medical Oncology) for randomised controlled trials (RCTs). Two review authors independently screened search results. We included RCTs examining G-CSF or GM-CSF in addition to standard therapy in patients with newly diagnosed M...Continue Reading

References

Jul 2, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess
Aug 5, 1989·BMJ : British Medical Journal·P J WilliamsonT J Hamblin
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Oct 18, 2007·Blood·Sophie ParkUNKNOWN GFM group (Groupe Francophone des Myélodysplasies)
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin JäderstenEva Hellström-Lindberg
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
Nov 6, 2009·The New England Journal of Medicine·Ayalew Tefferi, James W Vardiman
Feb 13, 2010·Leukemia Research·V SantiniUNKNOWN Italian Society of Hematology
Mar 20, 2010·Blood·Renée Beekman, Ivo P Touw
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M F FeyUNKNOWN ESMO Guidelines Working Group
Jul 2, 2010·Cancer Treatment Reviews·Rena BucksteinUNKNOWN Canadian Consortium on Evidence-based Care in MDS

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.